Skip to main content
Journal of Analytical Science and Technology

Table 2 Matrix effect of larotrectinib and IS (n = 5)

From: Development and validation of an LC-MS/MS method for monitoring larotrectinib, a tropomyosin-related kinase inhibitor, in mouse and human plasma and application to pharmacokinetic studies

 

Concentration (ng/mL)

Matrix effecta (%)

Mice

 Larotrectinib

5

110.73

15

110.72

500

91.23

8000

98.94

 IS (carbamazepine)

25

104.83

Human

 Larotrectinib

5

99.56

15

103.39

500

101.32

8000

102.00

 IS (carbamazepine)

25

100.09

  1. amean peak area of an analyte added post-precipitation (set 1)/mean peak area of the same analyte standards (set 2) × 100%
Back to article page